Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?



Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Signup for our daily newsletter and get our best articles emailed right to you!

  +Follow August 16, 2013 9:54AM



blog comments powered by Disqus

 Today's Must Reads

What Crowdfunding Leaders Are Saying About the SEC’s Approval of Title III

How the Drug Price Scrutiny is Affecting Pharma Stocks

8 More Tips for Choosing the Right Crowdfunding Platform

Will the Post-Smartphone Era Bring Wearable Drones?

3 Cloud Stocks That Pay Dividends


Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register